Objective To evaluate whether exposure to clomiphene citrate (CC) for ovulation induction is associated with major malformations overall or with specific fetal anomalies.
Introduction
Clomiphene citrate (CC), a first-line drug for the treatment of subfertility, is a nonsteroidal ovulation-inducing drug that has been used in humans for more than 40 years. 1 The frequency of use of CC according to recent studies is approximately 2%, 2, 3 and is currently rising. 4 CC has a relatively long elimination half-life of 5-7 days, and residues may be found in the bloodstream for up to 22 days and in stool samples even 6 weeks after intake.
The results of studies assessing the association between CC and birth defects have been inconclusive. [5] [6] [7] [8] CC has been reported to be associated with increased risks of central nervous system, cardiovascular, musculoskeletal, and *The first two authors have contributed equally to this article. urinary birth defects. 9 Specific defects that have been described include neural tube defect (NTD), 2, 10 anencephaly, 5 craniosynostosis, 5, 11 Dandy Walker malformation, 5 septal heart defects, 5, 12 coarctation of the aorta, 5 oesophageal atresia, 5 hypospadias, 13, 14 cloacal exstrophy, 5 and omphalocele. 5 We performed a population-based retrospective cohort study that examined births and terminated pregnancies to further investigate the association between exposure to CC and birth defects. We assessed the risk for major malformations overall and specific classes of birth defects.
Methods

Study population
We performed a retrospective cohort study including all women aged 15-49 years registered to the Clalit Health Services maintenance organisation in southern Israel who gave birth or underwent termination of pregnancy (for suspected congenital malformations) at Soroka Medical Center from 1998 to 2009. Conditions for exclusion included newborns/fetuses with chromosomal/genetic malformations, birth before 20 weeks of pregnancy, exposure to folic acid antagonist drugs during pregnancy, in vitro fertilization (IVF) treatments, and multiple pregnancies.
The exposure of interest was reported CC use in the period from 2 months before conception through the first month of pregnancy.
Databases
The data were collected from four different databases, three of which were computerised databases (medication dispensary database, deliveries database, and hospitalisation database) from the Soroka Medical Center and Clalit Health Services that draw information directly from original sources.
The Clalit Health Services medication dispense database records the drugs dispensed to all registered women, including the dates that the drugs were dispensed before and during pregnancy, the Anatomical Therapeutic Chemical (ATC) classification codes of the drugs (including the commercial and generic names), the dose schedules, and the dose dispensed in terms of the defined daily dose (i.e. the assumed average maintenance dose per day).
The Soroka Medical Center deliveries computerised database, housed in the Division of Obstetrics and Gynecology, contains information about all deliveries at Soroka Medical Center. Included in those data are maternal health status during pregnancy and delivery, maternal age, gestational age at delivery, perinatal death, parity, gravidity, ethnic group, past caesarean sections, past termination of pregnancy, pre-eclampsia and chronic hypertension, gestational and non-gestational diabetes, maternal anaemia, ovulation induction therapies, recurrent termination of pregnancy, self-reported smoking status during pregnancy, infant birthweight and Apgar scores at 1 and 5 minutes, multiple pregnancies, past premature deliveries, mode of delivery (vaginal, assisted, or caesarean section), intrauterine growth retardation (IUGR), labour induction method, delivery complications, placenta praevia, and placental abruption.
The Soroka Medical Center computerised hospitalization database, gathered from the Admit, Discharge, Transfer (ATD) computerised database, includes information about birth defects and illnesses of the newborn during the postpartum admission, and throughout the first year of life.
In addition, data on termination of pregnancy (for suspected congenital malformations) performed at Soroka Medical Center from 1998 to 2009 were collected from the registry of the Committee for Termination of Pregnancies. These data included information on maternal age, gestational age, past perinatal death, parity, gravidity with birth defects, ethnic group, drug abuse, self-reported smoking status during pregnancy, chronic maternal illness, radiation therapy (radium or cobalt), number of fetuses (according to recent ultrasound), chromosomal/genetic malformations, structural defects diagnosed by ultrasound or echocardiogram, and any illness, drug use, or any other aetiology that can cause damage to the fetus.
All listings of the four databases were encoded and linked by unique personal identification numbers (assigned at birth by the Interior Ministry and used throughout life) to create a new encoded registry of medications dispensed during pregnancy, and of pregnancy outcomes. All diagnoses are classified according to the International Classification of Diseases, 9th revision (ICD-9).
The study was approved by the local institutional ethics committee. In accordance with the Ministry of Health regulations, the institutional ethics committee did not require written informed consent because the data were anonymous.
Variable definitions
All CC formulations in Israel contain 50 mg of CC per tablet, and the drug is usually prescribed for 5 days at a dose of 50-100 mg per day. According to US Food and Drug Administration (FDA) guidelines, the dose can be increased up to 200 mg per day (four tablets), although it is not recommended that patients exceed 100 mg per day as CC has not been proven to be more effective at higher doses. 15 Follow-up for ovulation induction is recommended after each therapy cycle.
A pregnancy was counted as 'exposed' if CC was dispensed from 2 months before conception through the first month of pregnancy. Use of CC was also defined in terms of the total number of defined daily doses (DDDs) dispensed. The DDD for CC is 9 mg, as defined for the initial treatment of anovulation. The daily dosage may be increased by clinicians to achieve a more efficient clinical effect. 16 We divided the total DDDs dispensed into the following categories: 1-55, 56-60, and 61 mg or more. The unexposed group comprised all pregnancies in which CC was not taken over the course of the study period.
We used the definitions of major congenital malformations developed by the Metropolitan Atlanta Congenital Defects Program of the US Centers for Disease Control and Prevention (CDC). 1, 17, 18 Chromosomal/genetic diseases were excluded. Outcomes investigated for both live neonates and stillborns included major malformations in general and six different malformation subcategories: central nervous system (CNS) malformations (ICD-9 codes 740-743); congenital varicella syndrome (CVS) malformations (ICD-9 codes 745-747); gastrointestinal malformations (ICD-9 codes 750-751); genitourinary malformations (ICD-9 codes 752-753); musculoskeletal malformations (ICD-9 codes 754-756); and other systems (744, 748, and 757).
In subclass analyses of major malformations, the specific defects examined were: anencephaly (ICD-9 code 740); spina bifida (ICD-9 code 741); other anomalies of the nervous system (ICD-9 code 742); anomalies of the eye (ICD-9 code 743); anomalies of the ear, face, and neck (ICD-9 code 744), bulbus cordis anomalies and anomalies of cardiac septal closure (ICD-9 code 745); other anomalies of the heart (ICD-9 code 746), other anomalies of the circulatory system (ICD-9 code 747), anomalies of the respiratory system (ICD-9 code 748), cleft palate and lip (ICD-9 code 749), other anomalies of the upper alimentary tract (ICD-9 code 750), other anomalies of the digestive system (ICD-9 code 751), genital anomalies (ICD-9 code 752), anomalies of the urinary system (ICD-9 code 753), musculoskeletal deformities(ICD-9 code 754), other anomalies of the limbs (ICD-9 code 755), other musculoskeletal anomalies (ICD-9 code 756), anomalies of the integument (ICD-9 code 757), other perinatal jaundice (ICD-9 code 774.0), and congenital anomalies of the skull and face bones (ICD-9 code 756.0).
Statistical analysis
Statistical analyses were performed using SPSS 18 (IBM, Somers, NY, USA). In univariate analyses, we compared quantitative variables using Student's t-test or one-way ANOVA, and categorical data using chi-square or Fisher's exact tests. Odds ratios (ORs) were calculated with a 95% confidence interval (95% CI). We used multivariate logistic regression models to assess the independent risk for major malformations overall for six different subcategories of birth defects and for specific malformations in the newborns/fetuses of mothers exposed to CC. In addition, a dose-response association was examined by comparing subcategories of DDD in a multivariate logistic regression model.
Potential confounding factors included in the statistical analysis were maternal age, parity, the year of birth/termination of pregnancy, presence or absence of pre-pregnancy diabetes, self-reported smoking status during pregnancy, ethnic group (i.e. Jewish or Bedouin Muslim), and the use of gonadotropins/progesterone.
Results
Study population
During the study period, 114 961 pregnant women who were registered in Clalit Health Services were admitted to the Soroka Medical Center. Of these, 113 722 pregnancies ended in birth and 1239 ended in an induced termination of pregnancy. Of the pregnancies that ended in birth, 110 783 were singleton births and 4178 were multiple pregnancies. Of the induced terminations of pregnancy, 468 were for an ultrasound-detected malformation and 769 were for different medical reasons. After applying the inclusion and exclusion criteria, 100 589 pregnancies were left, 1872 of which had been exposed to CC. In each year of the study period, the percentage of the exposed group was relatively constant, varying from 1.7 to 2.7% of all pregnancies.
Maternal and birth characteristics
The characteristics of exposed and non-exposed pregnancies are summarised in Table 1 . Women exposed to CC were younger, more likely to be Jewish, and had significantly higher rates of prenatal follow-up and of exposure to gonadotropins/progesterone.
Outcomes
A total of 6109 infants (6.1%) were identified as having one or more major congenital malformations. The rate of major congenital malformations identified in the exposure group was 6.7% (126 of 1872 infants), compared with 6.1% (5983 of 98 876 infants) in the unexposed group (crude OR 1.12; 95% CI 0.93-1.34; adjusted OR 1.08; 95% CI 0.88-1.32). No significant association was found after studying subclasses of major congenital malformations (Table 2) .
There was no significant dose-response effect between exposure to CC and major congenital malformations (Table 3) .
In a univariate analysis of specific congenital malformations, CC was not associated with increased risk, excepting oesophageal atresia (crude OR 4.57; 95% CI 1.07-19.41), only two cases of which were found in the exposed group. No increased risk was found for specific malformations in the multivariate analysis. Specifically, the adjusted OR for anencephaly was 2.26 (95% CI 0.43-11.71), in spite of the relatively large number of cases (49), and the adjusted OR for oesophageal atresia was 3.68 (95% CI 0.65-20.76) ( Table 4) .
Discussion
Main findings
Despite the controversial data on the risk of associated birth defects, CC has been used extensively for more than four decades as a first-line drug for subfertility treatment. To date, however, most studies have used case-control designs, and all of them were limited by relatively small samples, 9 the pooling of exposure groups, and the retrospective collection of data. 2,10,13,14 Moreover, a major confounding variable inherent to this research is the risk of bias by indication, i.e. that the excess number of birth defects detected after CC use may be attributable to patient characteristics related to infertility rather than to the drug treatment. [19] [20] [21] In this large, population-based cohort study, we did not detect a significant association between CC use and rates of major malformations overall or specific anomalies after adjustment for maternal age, pre-pregnancy diabetes, parity, ethnicity, the calendar year in which the birth/termination of pregnancy took place, smoking, and the use of gonadotropins and progesterone. Even after dividing the *As a result of missing data, the sum of women is smaller than the total sum of exposed/not exposed women. CC-exposed group into subcategories of DDD, or according to specific malformations, no association was found between CC and fetal risk. The rate of major malformations overall and in the subcategories was higher than the rate in the general population, as reported by the Israeli Ministry of Health. These findings, however, may be attributed to the inclusion in our study of malformations in induced termination of pregnancy, in live and still births, and during the first year after birth, whereas the Ministry of Health reports only include the malformations that must be reported, and only in live and still births. 22 Higher rates of congenital malformations have been documented in Israel among Bedouins rather than among Jews, a finding that is possibly attributable to the relatively high rates of consanguineous marriage among Bedouins. 23, 24 The Soroka Medical Center databases contain information regarding alcohol abuse, but because a large portion of the district population comprises Jewish or Bedouin-Muslim religious communities, and because women of childbearing age in these communities rarely consume alcohol, none of the women in our study was diagnosed with alcohol abuse.
Some medications, especially folic-acid antagonists and anti-epileptic drugs, were previously found to be associated with CNS malformations. Although the current study did not detect an association between CC and fetal malformations, we re-analysed the data excluding these drugs and yielded similar results.
Although CC is the first line of therapy, aromatase inhibitors are another group of drugs used for ovulation induction. These drugs act by blocking estrogen biosynthesis, thereby reducing negative estrogenic feedback at the pituitary and increasing gonadotropin production, in a similar manner as CC. On the other hand, the chemical structure is different between the two medicines. Therefore, generalising the results of this study concerning CC to the aromatase inhibitors group would be inaccurate.
Strengths and limitations
The strengths of our study include its large populationbased cohort and its examination of the safety of CC use for over a decade, drawing from data comprising live births, still births, and terminations of pregnancy. Previous studies that did not include terminations of pregnancy may have introduced a bias towards the null hypothesis. 25 Although our report is limited in that exposure was defined according to an electronic medication database on drug dispensation, we assumed in our study that a dispensed *The DDD is the assumed average maintenance dose per day for a drug when it is used in adults for its main indication. For clomiphene citrate, the DDD is 9 mg. The unexposed group comprises infants of all women who did not take clomiphene citrate over the course of the study period. **Odds ratios were adjusted for maternal age, parity, year of birth/ termination of pregnancy, presence or absence of pre-pregnancy diabetes, self-reported smoking status during pregnancy, ethnic group, and the use of gonadotropins/progesterone. drug was also consumed. Indeed, the consistency between drug dispensation and consumption was studied in two different cohorts using the same databases, with the results showing over 90% adherence. 26 Although that study was conducted on illnesses for which therapeutic treatment is essential, our assumption about CC treatment compliance is based on the high likelihood that women with fertility problems, who are typically eager to try this treatment, will exhibit a high adherence rate. Further studies have also shown high correlations between drug dispensation and consumption in the general population, [27] [28] [29] and in pregnant women specifically. 30 Another potential limitation to our study is that our data on drug dispensation are based solely on health services in the community. Although this drug is not given during hospitalisation, its relatively low cost raises the possibility that part of our study population consumed the drug outside the framework of the healthcare services, and that part of our unexposed group was actually exposed, thus biasing the results toward the null hypothesis. We therefore assumed that the incidence of CC dispensation and consumption via routes outside of the community health services is negligible. Moreover, because of the very large size of our unexposed group, even if it does contain a group of exposed individuals, the small size of that group renders its effects statistically negligible.
Inherent in all such studies is the risk of bias by indication, as subfertility may cause malformations irrespective of treatment. The potential for this bias in our study is, however, probably irrelevant in light of the negative results obtained for exposure to CC and birth malformations.
Interpretation
Our findings are consistent with the results of several studies that found no significant risk for CNS malformations or for NTD, 7, 8 or for genitourinary system malformations or hypospadias. 5, 6 In contrast, a case-control study reported that CC use was associated with significant risk for anencephaly, craniosynostosis, Dandy Walker malformation, septal heart defects, muscular ventricular septal heart defects (VSDs), coarctation of the aorta, oesophageal atresia, cloacal exstrophy, and omphalocoele. 5 This casecontrol study, however, was based on the women's selfreported drug consumption, which entails a serious risk of recall bias in addition to a possible selection bias, as 35% of the study group did not participate in the final analysis. Furthermore, only a univariate analysis was conducted. 5 
Conclusion
In summary, this large population-based retrospective cohort study fails to show an increased risk for major malformations overall or for specific anomalies. These data can reassure both healthcare providers and patients about the safety of using CC to induce ovulation.
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